Prescribing patterns for Alzheimer disease: Survey of Canadian family physicians;Modes de prescription pour la maladie d'Alzheimer: Enquête auprès des médecins de famille canadiens

Canadian Family Physician

Volumn 52, Issue FEB., 2006, Pages 208-209

  Hillmer, Melinda ^a   Krahn, Murray ^b,c   Hillmer, Michael ^c   Pariser, Pauline ^a,d   Naglie, Gary ^c,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e TORONTO REHABILITATION INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; CANADA; CLINICAL PRACTICE; DRUG EFFICACY; FEMALE; GENDER; GENERAL PRACTITIONER; HEALTH SURVEY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; MEDICAL EDUCATION; PERCEPTION; PREDICTION; PRESCRIPTION; QUESTIONNAIRE; SELF REPORT;

ALZHEIMER DISEASE; CANADA; CHOLINESTERASE INHIBITORS; CROSS-SECTIONAL STUDIES; FAMILY PRACTICE; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; SEX FACTORS;

EID: 33744461294     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Canadian Study of Health and Aging: study methods and prevalence of dementia. CMAJ 1994;150:899-913.
2. National Institute for Health and Clinical Excellence. Donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. Report 19. London, UK: National Institute for Clinical Excellence; 2001. Available at: www.nice.org.uk. Accessed 2005 November 23.
3. Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Einarson TR. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003;169:557-64.
4. Birks J, Grimley Evans J, Jakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2000;4:CD001191.
5. Olin JT, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2002;3:CD001747.
6. Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, et al. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther 2002;24:862-86.
7. Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2003;3:CD001190.
8. Trinh N-H, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003;289:210-6.
9. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105-15.
10. Patterson CJ, Gauthier S, Bergman H, Cohen CA, Feightner JW, Feldman H, et al. Canadian Consensus Conference on Dementia: a physician's guide to using the recommendations. CMAJ 1999;160:1738-42.
11. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-66.
12. Oremus M, Wolfson C. Factors influencing the prescribing of cholinesterase inhibitors to Alzheimer's disease patients [abstract]. Geriatr Today: J Can Geriatr Soc 2003;6:65.
13. Edwards P, Roberts I, Clarke M, Di Guiseppi C, Pratap S, Wentz R, et al. Increasing response rates to postal questionnaires: systematic review. BMJ 2002;324:1183-5.
14. Hosmer DW, Taber S, Lemeshow S. The importance of assessing the fit of logistic regression models: a case study. Am J Public Health 1991;81:1630-5.
15. Ash AS, Shwartz M. Evaluating the performance of risk-adjustment methods: dichotomous measures. In: Iezzono LI, editor. Risk adjustment for measuring health care outcomes. Ann Arbor, Mich: Health Administration Press; 1994. p. 423.
16. Carroll NV. How effectively do managed care organizations influence prescribing and dispensing decisions? Am J Manag Care 2002;8:1041-54.
17. Godwin M, Chapman J, Mowat D, Racz W, McBride J, Tang J. Delisting of drugs in Ontario. How attitudes and prescribing strategies of family physicians in the Kingston area changed. Can Fam Physician 1996;42:1309-16.
18. Davidson W, Molloy DW, Somers G, Bedard M. Relation between physician characteristics and prescribing for elderly people in New Brunswick. CMAJ 1994;150:917-21.
19. Henderson JT, Weisman CS. Physician gender effects on preventive screening and counseling: an analysis of male and female patients' health care experiences. Med Care 2001;39:1281-92.
20. Rosen MP, Davis RB, Lesky LG. Utilization of outpatient diagnostic imaging. Does the physician's gender play a role? J Gen Intern Med 1997;12:407-11.
21. Hux JE, Melady MP, DeBoer D. Confidential prescriber feedback and education to improve antibiotic use in primary care: a controlled trial. CMAJ 1999;161:388-92.
22. Dillman DA. Survey implementation. In: Mail and Internet surveys: the tailored design method. 2nd ed. New York, NY: John Wiley & Sons, Inc; 1999. p. 167-70.